Leerink analyst Joseph P. Schwartz raised the firm’s price target on KalVista (KALV) to $20 from $18 and keeps an Outperform rating on the shares. The firm notes the FDA approved Ekterly as the first and only on-demand treatment for hereditary angioedema attacks. Leerink believes this is a launch investors will want to own.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KALV:
- Buy Rating for KalVista Pharmaceuticals Driven by FDA Approval and Strategic Market Entry of Ekterly
- KalVista price target raised to $40 from $32 at Jefferies
- Musk to launch new political party, Trump threatens BRICS tariff: Morning Buzz
- KalVista Pharmaceuticals Gains FDA Approval for EKTERLY®
- KalVista announces FDA approval for EKTERLY